Tesamorelin Compounding Guidance Update: FDA Warning on GLP-1 Drugs May Impact GHRH Analog Oversight

A clinician I spoke with recently mentioned a patient who had been paying around $200 a month for compounded tesamorelin, a growth hormone-releasing hormone (GHRH) analog, to reduce visceral adipose tissue. The patient was concerned after reading about the FDA's latest warning letters targeting compounded semaglutide, a GLP-1 receptor agonist. The worry was that the regulatory heat on GLP-1 compounding might spill over and restrict access to GHRH analogs like tesamorelin. This concern is not unfounded. The FDA's recent actions against compounded semaglutide signal a broader scrutiny of peptide compounding, and tesamorelin, which exists in a similar regulatory gray zone, could be next.

FDA's GLP-1 Warning Letters: A Template for GHRH Oversight

In 2023 and 2024, the FDA issued multiple warning letters to compounding pharmacies and telehealth companies marketing compounded semaglutide. The agency cited concerns about unapproved drug products, potential impurities, and misleading claims. A key issue was the use of semaglutide sodium or semaglutide acetate, salt forms not found in the FDA-approved product, which raised safety questions. The FDA's stance was clear: compounding semaglutide is not permissible when the approved drug is available, unless a specific patient need exists. This reasoning could easily extend to tesamorelin, which is available as the FDA-approved Egrifta. The FDA has already shown interest in peptide compounding oversight, as seen in its 2023 guidance on peptide impurity risks, which directly impacts GHRH analogs. A deeper look at that guidance reveals the agency's focus on the quality of active pharmaceutical ingredients used in compounding, a point that applies squarely to tesamorelin sourced from bulk suppliers.

503A vs. 503B: The Compounding Distinction Under Pressure

Compounding pharmacies operate under two sections of the Federal Food, Drug, and Cosmetic Act: 503A for traditional compounding and 503B for outsourcing facilities. 503A pharmacies compound for individual patients based on prescriptions, while 503B facilities can produce larger batches without patient-specific prescriptions but must follow current good manufacturing practices. For tesamorelin, many 503A pharmacies have been compounding it using bulk drug substances, often from unregistered foreign facilities. The FDA's recent warning letters on semaglutide emphasized that compounding using bulk drug substances is not allowed when an FDA-approved product is available, unless the substance appears on the FDA's bulk drug substances list. Tesamorelin is not on that list. This puts 503A compounders in a precarious position. A 503B facility might have more leeway if it can demonstrate clinical need, but the FDA has not explicitly approved tesamorelin for compounding. The semaglutide crackdown suggests the FDA is willing to enforce these distinctions aggressively, and tesamorelin compounders could face similar scrutiny.

Industry Response: Compounders Brace for Impact

Compounding pharmacists I've spoken with are watching the semaglutide situation closely. One pharmacist noted that the FDA's focus on salt forms and impurity profiles in semaglutide could translate to heightened scrutiny of tesamorelin's sourcing and purity. Many compounders rely on certificates of analysis from suppliers, but the FDA has questioned the reliability of these documents. The Alliance for Pharmacy Compounding has advised members to review their sourcing and documentation for all peptide compounds. Some large compounding pharmacies have already started limiting their peptide offerings, anticipating further FDA action. The cost of compliance could rise, potentially increasing prices for patients. A vial of compounded tesamorelin currently costs around $48 to $75, but if compounders must switch to more expensive, FDA-registered sources or undergo additional testing, that price could climb. The economic pressure might push some compounders out of the peptide market entirely.

What Practitioners Are Watching: Clinical Implications and Evidence Quality

Clinicians prescribing compounded tesamorelin are concerned about continuity of care. A 2022 study (PubMed) showed tesamorelin's efficacy in reducing visceral fat, but the evidence quality for compounded versions is a 2 of 3 at best, given variability in purity and potency. Practitioners are also monitoring the FDA's stance on other peptides like MOTS-c and BPC-157, which are often compounded alongside tesamorelin. A 2023 case report described a patient who experienced injection-site reactions from a compounded peptide blend, highlighting the risks. The FDA's warning on semaglutide mentioned similar adverse events, and practitioners worry that increased oversight could lead to a crackdown on all compounded peptides, not just GLP-1s. Some are exploring alternatives like retatrutide, a triple agonist still in clinical trials, but that raises its own compounding questions. Others are turning to topical peptides like Argireline, which fall outside traditional compounding regulations. The landscape is shifting, and practitioners are seeking clear guidance from professional organizations.

Likely Trajectory: More Enforcement, Tighter Standards

The FDA's actions on semaglutide are likely a preview of what's to come for GHRH analogs. The agency has signaled that it will prioritize enforcement against compounders that pose the greatest risk to public health, and tesamorelin, with its potential for immunogenicity and impurity-related adverse events, fits that profile. The FDA may issue specific guidance on GHRH analog compounding, similar to its recent peptide impurity guidance. This could include requirements for endotoxin testing, sterility assurance, and potency verification. For patients and prescribers, this means that access to compounded tesamorelin may become more restricted, but the product that remains available could be safer. The compounding industry will likely see consolidation, with larger 503B facilities dominating the market. The days of easily obtaining compounded tesamorelin from a telehealth prescriber may be numbered, but the trade-off could be a more reliable supply chain. For now, the regulatory pendulum is swinging toward tighter oversight, and the GHRH analog space is in its path.

This article discusses peptides as research compounds. It is not medical advice.